- Home
- Special Topics
- Disease areas
- Neurodegenerative diseases
This page brings together the Agency's latest information on diseases causing problems with the brain and nervous system, including Alzheimer's disease, Parkinson's disease and multiple sclerosis. It lists:
the ten newest and recently updated medicines authorised for the treatment of neurodegenerative diseases in the European Union (EU);
the most recent opinions on medicines for neurodegenerative diseases that are pending authorisation by the European Commission (EC);
the latest news and press releases related to neurodegenerative diseases;
the Agency's events on topics related to neurodegenerative diseases.
New and recently updated medicines
-
01/02/2013
human
-
24/04/2012
human
-
07/02/2013
human
-
07/02/2013
human
-
22/05/2006
human
-
12/04/2013
human
-
04/02/2013
human
-
16/05/2013
human
-
21/03/2013
human
-
12/03/2013
human
Opinions pending EC decision
-
21/03/2013
human
-
21/02/2013
human
-
21/02/2013
human
News
22/03/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2013
This page provides an overview of the opinions adopted at the March 2013 meeting of the CHMP and other important outcomes. ... Read more
22/02/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 February 2013
This page provides an overview of the opinions adopted at the February 2013 meeting of the CHMP and other important outcomes. ... Read more
18/01/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 2013
This page provides an overview of the opinions adopted at the January 2013 meeting of the CHMP and other important outcomes. ... Read more
11/01/2013
FGK Representative Service GmbH withdraws its marketing-authorisation application for Memantine FGK (memantine)
The European Medicines Agency has been formally notified by FGK Representative Service GmbH of its decision to withdraw its application for centralised marketing authorisation for the medicine Memantine FGK (memantine), 7 mg, 14 mg, 21 mg and 28 mg, prolonged-release hard capsule. ... Read more
19/10/2012
European Medicines Agency recommends approval of first radiopharmaceutical for PET imaging of β-amyloid neuritic plaque density
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Amyvid (florbetapir 18F) as a diagnostic agent in patients who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. ... Read more
19/10/2012
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2012
At the start of its October 2012 meeting, the CHMP elected Dr Ian Hudson as its new vice-chair for a three-year mandate. ... Read more
09/10/2012
European Medicines Agency invites feedback on the draft guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a draft guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. ... Read more
21/09/2012
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2012
At the start of its September 2012 meeting, the Committee for Medicinal Products for Human Use (CHMP) elected Tomas Salmonson as its new chair for a three-year mandate. ... Read more
20/09/2012
World Alzheimer's Month: September 2012
The European Medicines Agency supports World Alzheimer's Month which is taking place throughout September 2012. ... Read more
06/07/2012
European Medicines Agency finalises update to Parkinson's disease guideline
The European Medicines Agency has published an update to its guidance for pharmaceutical companies developing medicines for Parkinson's disease. ... Read more
Events
08/11/2010
EMA
Expert meeting in familial neurodegenerative disorders
This meeting is creating a forum for discussion among stakeholders - academics, regulators, industry and patients - in order to provide a first approximation for the resolution of issues in familial neurodegenrative disorders. Autosomal dominant Alzheimer's disease (ADAD) and Huntington's disease (HD) are being used as models to illustrate the challenges in pre-symptomatic clinical design studies. The insights obtained from this discussion are expected to be applicable to other similar areas. ... Read more
02/10/2006
CHMP
European Medicines Agency workshop - Slowing the progression of neurodegenerative diseases
This workshop is involving a panel of European experts actively involved in the clinical research of disease modifiers for neurodegenerative diseases. The workshop is allowing participants to convey their respective views and identify a common ground of enrichment between researchers and regulators. ... Read more
13/10/2008
CHMP
Workshop on clinical outcome measures and endpoints for efficacy assessment in spinal muscular atrophy
This workshop is covering spinal muscular atrophy, including potential biomarkers and clinical trials. ... Read more
16/05/2008 - 17/05/2008
EMA
Brain diseases in the elderly
This is a joint workshop with the European School for Scientific and Regulatory Assessment of New Medicines and the European Medicines Agency on brain diseases in the elderly. ... Read more
11/02/2008
CHMP
Second European Medicines Agency workshop on neurodegenerative diseases: Focus on dementia
This workshop is involving a panel of European experts actively involved in clinical and non-clinical research into dementia. The United States Food and Drug Administration is contributing to the debate on the current regulatory requirements in terms of development of new medicines for dementia. The workshop is expected to allow the participants to convey their respective views and identify a common ground of enrichment between academia, patients, healthcare professionals, industry and regulators. The elements originating during the discussion will not constitute a formal specific advice on ... Read more
25/09/2009
EMA
TREAT-NMD workshop on the development of antisense oligonucleotide therapies for Duchenne muscular dystrophy
This workshop is addressing the development of antisense oligonucleotides in the treatment of Duchenne muscular dystrophy. ... Read more